bedaquiline

Bedaquiline (R207910) is an anti-tuberculosis drug which selectively inhibit the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis.

Bedaquiline fumarate (TMC207), a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections. It blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called diarylquinolines.

(1S,2R)-Bedaquiline ((1S,2R)-TMC207) is a pharmaceutical intermediate utilized in the synthesis of various active compounds.

UH-NIP-16 exhibits antibacterial activity against Mycobacterium tuberculosis, effectively inhibiting the pathogenic mycobacterium strains H37Rv and CDC1551 with MIC50 values of 1.86 and 3.05 μM, respectively. Additionally, UH-NIP-16 synergistically enhances the antitubercular effects when used with antituberculosis agents such as Streptomycin, Isoniazid, Ethambutol, and Bedaquiline.

(Rac)-TBAJ-876, a racemate of its counterpart TBAJ-876, acts as an inhibitor of Mycobacterium tuberculosis. It is an analogue of the anti-tuberculosis agent Bedaquiline, indicating its potential in tuberculosis research.